Home -> Law Blog Directory -> Patent Law Blogs -> Patently Obvious
(866) 635-2689 for Personal Injury or (866) 635-9402 for Criminal Defense
Find a Local Lawyer
Divorce (866) 635-6190
Personal Injury (866) 635-2689
Criminal Defense (866) 635-9402
Patent Law
: Patently ObviousBPAI Review of Obviousness Rejections
By Dennis Crouch
Ex parte Quist (BPAI 2010) (precedential opinion)
In only its second precedential opinion of 2010, the Board of Patent Appeals and Interferences (BPAI) has further developed its procedures for its review of obviousness rejections and consideration of evidence of nonobviousness.
On Board review, if the appellant raises the issue as to whether the examiner?s conclusion of obviousness was in error, based in part on the proffered evidence of secondary considerations, the panel must consider if the examiner erred in determining patentability, based upon the totality of the record. In such instances, the Board panel must consider anew all the relevant evidence of obviousness, both for and against, in view of the argument on the issue. One such instance requiring a reweighing is seen in the present appeal ? if the Appellants argue that the Examiner erred in determining that the weight of the evidence supports a conclusion of obviousness, the Board must review that conclusion of obviousness anew to see if the preponderance of relevant evidence properly before the Office supports that conclusion.
This decision should be seen as a continuation of the Ex parte Frye (BPAI 2010) holding that the Board must review "the particular finding(s) contested by an appellant anew in light of all the evidence and argument on that issue.?
Despite taking a fresh look at the evidence and conclusions, the BPAI held that the examiner had been correct in determining that the claimed "process for the manufacturing of decorative boards with an abrasion resistant surface and edges" was indeed obvious.
Over 85% of BPAI appeals focus on obviousness. The BPAI has a current backlog of over 16,000 cases. At its current rate of disposal, this figure represents a 29-month backlog.
Full post as published by Patently Obvious on June 27, 2010 (boomark / email).
FDA Issues Update on Safety Review Orlistat
Orlistat FDA Issues Update on Safety Review
Aurora Loan Faces Class Action over Mortgage Review Services
Aurora Loan Faces Class Action over Mortgage Review Services
FDA Review of Prostate Cancer Treatment Prompts Warning of Risk for Diabetes
Prostate Cancer Treatment FDA Review Prompts Warning of Risk for Diabetes
Xigris
Study Prompts FDA Safety Review
Lipitor
Review of Studies Show No Significant Benefit in Women
Wrinkle-Fillers
FDA to Review Labeling due to Adverse Event Reports

Ex parte Fu and obviousness rejections over a genus
Webinar on Obviousness after KSR
BPAI Starts Issuing Decisions on NTP/RIM Patent Reexaminations
BPAI: when prior art teaches away, expectation of success cannot support obviousness rejection
Ex Parte Matsuoka: the case for prima facie non-obviousness







